LENZ vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCM
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
LENZ Therapeutics vs. Its Competitors
LENZ Therapeutics (NASDAQ:LENZ) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, LENZ Therapeutics had 2 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 4 mentions for LENZ Therapeutics and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.82 beat LENZ Therapeutics' score of 0.74 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
LENZ Therapeutics currently has a consensus price target of $46.60, indicating a potential upside of 43.23%. MoonLake Immunotherapeutics has a consensus price target of $74.50, indicating a potential upside of 60.68%. Given MoonLake Immunotherapeutics' higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than LENZ Therapeutics.
MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
LENZ Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
LENZ Therapeutics' return on equity of -23.74% beat MoonLake Immunotherapeutics' return on equity.
Summary
LENZ Therapeutics beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LENZ) was last updated on 7/5/2025 by MarketBeat.com Staff
